23 May 2013
Keywords: gsk, elects, exercise, xl784, option, uk, drug
Article | 28 January 2008
UK drug major GlaxoSmithKline has decided not to exercise its option to license the candidate diabetic nephropathy drug XL784 from ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 January 2008
© 2013 thepharmaletter.com